Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany
Abstract Background Despite recommendations from the German Standing Committee on Vaccination (STIKO), pneumococcal vaccination coverage remains low in vulnerable populations. This study estimated the pneumococcal vaccination coverage rate (VCR) and timing among individuals aged 16–59 years in Germa...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-09-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-022-07736-1 |
| _version_ | 1811253571069411328 |
|---|---|
| author | Arijita Deb Bélène Podmore Rosemarie Barnett Dominik Beier Wolfgang Galetzka Nawab Qizilbash Dennis Haeckl Timo Boellinger Kelly D. Johnson Thomas Weiss |
| author_facet | Arijita Deb Bélène Podmore Rosemarie Barnett Dominik Beier Wolfgang Galetzka Nawab Qizilbash Dennis Haeckl Timo Boellinger Kelly D. Johnson Thomas Weiss |
| author_sort | Arijita Deb |
| collection | DOAJ |
| description | Abstract Background Despite recommendations from the German Standing Committee on Vaccination (STIKO), pneumococcal vaccination coverage remains low in vulnerable populations. This study estimated the pneumococcal vaccination coverage rate (VCR) and timing among individuals aged 16–59 years in Germany who were recommended to receive pneumococcal vaccination, according to STIKO. Methods A retrospective cohort analysis was conducted using the German InGef database. Individuals aged 16 to 59 years diagnosed with at least one “at-risk” (chronic disease) or “high-risk” (e.g., immunocompromising) condition considered to be at-risk of pneumococcal infection were identified at the time of first diagnosis, between January 1, 2016 and December 31, 2018, and followed up until December 31, 2019. The percentage of cumulative pneumococcal VCR with 95% confidence interval (CI) was reported for each calendar year of follow-up. Results There were 334,292 individuals followed for a median of 2.38 (interquartile range (IQR) 1.63–3.13) person years. For individuals aged 16–59 years diagnosed with an incident risk condition in 2016, pneumococcal VCR increased from 0.44% (95% CI 0.41–0.48) in 2016 to 1.24% (95% CI 1.18–1.30) in 2019. In 2019, VCRs were higher in individuals with high-risk conditions compared with at-risk conditions (2.24% (95% CI 2.09–2.40) vs. 0.90% (95% CI 0.85–0.96)). In 2019, VCRs were higher in individuals aged 50 to 59 years compared with individuals aged 16 to 49 years (2.25% (95% CI 2.10–2.41) vs. 0.90% (95% CI 0.84–0.96)). Similar trends were observed in individuals with newly diagnosed risk conditions identified in 2017 and in 2018. Older age, influenza vaccination and increasing number of risk conditions increased the likelihood of pneumococcal vaccination. Median time to vaccination from diagnosis of the risk condition was shorter for high-risk conditions (369.5 days (IQR 155.8–702.0)) compared to at-risk conditions (435.5 days (IQR 196.3–758.8)). Conclusion Despite recommendations from STIKO, pneumococcal vaccination coverage remains very low and with long delays in vulnerable individuals aged 16–59 in Germany. Further efforts are required to increase immunization levels and shorten time to vaccination among individuals 16–59 years of age developing conditions with higher susceptibility to pneumococcal infection. |
| first_indexed | 2024-04-12T16:52:56Z |
| format | Article |
| id | doaj.art-9c65cf8423474b60bd31244606b1aaf0 |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-04-12T16:52:56Z |
| publishDate | 2022-09-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-9c65cf8423474b60bd31244606b1aaf02022-12-22T03:24:21ZengBMCBMC Infectious Diseases1471-23342022-09-0122111110.1186/s12879-022-07736-1Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in GermanyArijita Deb0Bélène Podmore1Rosemarie Barnett2Dominik Beier3Wolfgang Galetzka4Nawab Qizilbash5Dennis Haeckl6Timo Boellinger7Kelly D. Johnson8Thomas Weiss9Merck & Co., IncOXON EpidemiologyOXON EpidemiologyInGef-Institute for Applied Health Research Berlin GmbHInGef-Institute for Applied Health Research Berlin GmbHOXON EpidemiologyWIG2 GmbHMSD Sharp & Dohme GmbHMerck & Co., IncMerck & Co., IncAbstract Background Despite recommendations from the German Standing Committee on Vaccination (STIKO), pneumococcal vaccination coverage remains low in vulnerable populations. This study estimated the pneumococcal vaccination coverage rate (VCR) and timing among individuals aged 16–59 years in Germany who were recommended to receive pneumococcal vaccination, according to STIKO. Methods A retrospective cohort analysis was conducted using the German InGef database. Individuals aged 16 to 59 years diagnosed with at least one “at-risk” (chronic disease) or “high-risk” (e.g., immunocompromising) condition considered to be at-risk of pneumococcal infection were identified at the time of first diagnosis, between January 1, 2016 and December 31, 2018, and followed up until December 31, 2019. The percentage of cumulative pneumococcal VCR with 95% confidence interval (CI) was reported for each calendar year of follow-up. Results There were 334,292 individuals followed for a median of 2.38 (interquartile range (IQR) 1.63–3.13) person years. For individuals aged 16–59 years diagnosed with an incident risk condition in 2016, pneumococcal VCR increased from 0.44% (95% CI 0.41–0.48) in 2016 to 1.24% (95% CI 1.18–1.30) in 2019. In 2019, VCRs were higher in individuals with high-risk conditions compared with at-risk conditions (2.24% (95% CI 2.09–2.40) vs. 0.90% (95% CI 0.85–0.96)). In 2019, VCRs were higher in individuals aged 50 to 59 years compared with individuals aged 16 to 49 years (2.25% (95% CI 2.10–2.41) vs. 0.90% (95% CI 0.84–0.96)). Similar trends were observed in individuals with newly diagnosed risk conditions identified in 2017 and in 2018. Older age, influenza vaccination and increasing number of risk conditions increased the likelihood of pneumococcal vaccination. Median time to vaccination from diagnosis of the risk condition was shorter for high-risk conditions (369.5 days (IQR 155.8–702.0)) compared to at-risk conditions (435.5 days (IQR 196.3–758.8)). Conclusion Despite recommendations from STIKO, pneumococcal vaccination coverage remains very low and with long delays in vulnerable individuals aged 16–59 in Germany. Further efforts are required to increase immunization levels and shorten time to vaccination among individuals 16–59 years of age developing conditions with higher susceptibility to pneumococcal infection.https://doi.org/10.1186/s12879-022-07736-1Pneumococcal diseasePneumococcal vaccinationPneumococcal conjugate vaccinePCV13PPSV23Vaccine coverage rate |
| spellingShingle | Arijita Deb Bélène Podmore Rosemarie Barnett Dominik Beier Wolfgang Galetzka Nawab Qizilbash Dennis Haeckl Timo Boellinger Kelly D. Johnson Thomas Weiss Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany BMC Infectious Diseases Pneumococcal disease Pneumococcal vaccination Pneumococcal conjugate vaccine PCV13 PPSV23 Vaccine coverage rate |
| title | Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany |
| title_full | Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany |
| title_fullStr | Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany |
| title_full_unstemmed | Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany |
| title_short | Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany |
| title_sort | pneumococcal vaccination coverage in individuals 16 59 years with a newly diagnosed risk condition in germany |
| topic | Pneumococcal disease Pneumococcal vaccination Pneumococcal conjugate vaccine PCV13 PPSV23 Vaccine coverage rate |
| url | https://doi.org/10.1186/s12879-022-07736-1 |
| work_keys_str_mv | AT arijitadeb pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany AT belenepodmore pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany AT rosemariebarnett pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany AT dominikbeier pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany AT wolfganggaletzka pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany AT nawabqizilbash pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany AT dennishaeckl pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany AT timoboellinger pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany AT kellydjohnson pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany AT thomasweiss pneumococcalvaccinationcoverageinindividuals1659yearswithanewlydiagnosedriskconditioningermany |